Samsung Biologics to make Moderna vaccine in Biden summit takeaway

Incheon production deal comes after Moon government faced criticism on supply front

20210524N samsung vials

Samsung Biologics will produce hundreds of millions of Moderna vaccines starting this summer. (Photo courtesy of Samsung Biologics)

KOTARO HOSOKAWA, Nikkei staff writer

SEOUL -- South Korean drugmaker Samsung Biologics will begin producing the Moderna coronavirus vaccine following an agreement struck during President Moon Jae-in's trip to Washington last week.

The company will produce hundreds of millions of vaccine doses at its facilities in Incheon and plans to ship the drug domestically and to other destinations excluding the U.S., according to Sunday's announcement.

Sponsored Content

About Sponsored ContentThis content was commissioned by Nikkei's Global Business Bureau.